<DOC>
	<DOC>NCT03013881</DOC>
	<brief_summary>The purpose of the study is to evaluate the safety, tolerability, and pharmacokinetics of escalating single-dose of UB-921 in healthy male volunteers.</brief_summary>
	<brief_title>A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of UB-921 in Healthy Volunteers</brief_title>
	<detailed_description>This is an open-label, two-part, dose-escalation and comparative pharmacokinetics (PK) study of UB-921 in healthy male volunteers. Eligible volunteers will be sequentially enrolled into 3 escalating-dose cohorts at a study site. After administration of a single-dose intravenous infusion of UB-921, subjects will be followed for 63 days and monitored for safety, tolerability, and PK parameters.</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<criteria>Total body weight â‰§50 kg (110 lbs) No clinically relevant abnormalities To agree on using birth control barrier (eg. male condom) during the entire study period. Signing the written informed consent form Previous exposure to chimeric, humanized or human monoclonal antibody, whether licensed or investigational A history of drug abuse or heavy drinking. Blood donation over 250 mL within 90 days prior to the screening Not in the condition to participate in this study considered by investigator(s)</criteria>
	<gender>Male</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>UB-921</keyword>
	<keyword>anti-HER2 monoclonal antibody</keyword>
	<keyword>breast neoplasm</keyword>
	<keyword>breast cancer</keyword>
	<keyword>Herceptin</keyword>
	<keyword>Trastuzumab</keyword>
	<keyword>HER2</keyword>
</DOC>